David Pass
President & Chief Executive Officer AltrixBio Inc.
Seminars
Thursday 16th July 2026
Unique Targeting of the Gut for Metabolic Benefit
4:10 pm
- Leveraging bariatric bypass clinical insights with novel oral small-molecule pharmaceuticals
- Synergy with rapidly evolving metabolic armamentarium
- Well-tolerated and effective early treatment choice alongside metformin and SGLT2s while complementing incretin-based therapies
